Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024
February 26 2024 - 8:30AM
Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company
focused on skin and hair health (“Carmell” or the “Company”), today
announced that they have completed product development of their
Gold Limited Edition Exclusive (G.L.E.E.) product for commercial
launch in March 2024. Additionally, the Company is in advanced
stages of development and testing of 9 other skincare products
anticipated to launch over Spring and Summer 2024.
The Carmell skincare product portfolio:
- Carmell G.L.E.E. – limited edition
exclusive product by invitation only. Launching in March 2024.
- Youth Restoring formula – daily
cream to reduce the appearance of wrinkles and blemishes.
- Treatment Enhancing formula – for
use by professional care providers to soothe and repair the skin
barrier following aesthetic treatments.
- Rapid Recovery formula – for use by
professional care providers to accelerate recovery.
- Undereye AM formula – reduce the
appearance of dark circles and crepey skin as well as
photoprotection during the daytime.
- Undereye PM formula – calm and
strengthen undereye skin at bedtime.
- Ultra-Brightening formula – extra
strength anti-blemish and skin brightening action.
- Ultra-Hydrating formula – extra
strength skin hydrating and plumping action.
- Ultra-Gentle formula – formulated
for daily use for the most sensitive skin types.
- MotherCare formula – formulated for
sensitive and mechanically stressed skin during pregnancy.
Carmell’s suite of skincare products are based
on the Carmell SecretomeTM, a potent cocktail of 1000+ growth
factors and proteins extracted from allogeneic human platelets
sourced from US FDA-approved tissue banks. The technology
underpinning the Carmell Secretome has been extensively tested for
safety and efficacy, significantly surpassing standards set by the
Cosmetics Industry, including robust results from a prospective,
randomized, multi-center Phase 2 human trial.
Besides the Carmell SecretomeTM, the Company has
developed a novel micellar nanoparticle formulation that enables
delivery of lipophilic and hydrophilic ingredients without relying
on the Foul FourteenTM, 14 potentially harmful excipients that are
commonly used by other companies to impart texture, stability and
other desirable physicochemical attributes to cosmetic products.
Additionally, Carmell’s micellar formulations do not utilize
mineral or vegetable oils across their entire product line and are
designed to be non-comedogenic.
In addition to the aforementioned skincare
products, Carmell is also developing a Men’s Skincare Line and a
topical Haircare line of products. Carmell benefits from the
ongoing guidance around product development and testing from a
Scientific Advisory Board comprised of a dozen Key Opinion Leaders
associated with the best technology advancements in the Aesthetics
Industry.
Carmell products are manufactured in-house at
their Pittsburgh facility in compliance with current Good
Manufacturing Practice (cGMP) guidelines. Reflecting their
commitment to quality, Carmell has developed and implemented a
robust panel of tests covering everything from raw materials to
in-process testing to final product testing as tracked and
documented by their fully electronic Quality Management System.
Carmell’s manufacturing processes surpass several guidelines in the
proposed Modernization of Cosmetic Regulations Act (U.S. Food and
Drug Administration) anticipated to be effective July 1, 2024. In
preparation for at-scale commercial operations, Carmell has set up
a fully functional online store integrated with Oracle NetSuite on
the backend and logistics partners on the frontend.
About CarmellCarmell is a
bio-aesthetics company that utilizes the human platelet secretome
to topically deliver more than a thousand proteins and growth
factors to support skin and hair health. Carmell’s quality ethos is
based on rational cosmetics design coupled with a focus on clean
formulas that omit the Foul Fourteen, 14 commonly used chemicals
that may cause harm to our health. The Company is focused on
developing topical cosmetics tailored to meet the demanding
technical requirements of professional care providers and
discerning retail consumers. For more information,
visit www.carmellcosmetics.com
Forward-Looking StatementsThis
press release contains forward-looking statements that are based on
beliefs and assumptions and information currently available. In
some cases, you can identify forward-looking statements by the
following words: “may,” “will,” “could,” “would,” “should,”
“expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “ongoing” or the
negative of these terms or other comparable terminology. However,
not all forward-looking statements contain these words. These
statements involve risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Although
we believe that we have a reasonable basis for each forward-looking
statement contained in this press release, we caution you that
these statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about the
attributes and benefits of Carmell’s products including R&D
products under development. We cannot assure you that the
forward-looking statements in this press release will prove to be
accurate. These forward-looking statements are subject to a number
of significant risks and uncertainties that could cause actual
results to differ materially from expected results, including,
among others, the ability to recognize anticipated benefits from
their commercial products, R&D pipeline, distribution
agreements, changes in applicable laws or regulations, the
possibility that Carmell may be adversely affected by other
economic, business, and/or competitive factors, and other risks and
uncertainties, including those to be included under the header
“Risk Factors” in the 10-Q statement on filed by Carmell with the
SEC on November 15, 2023, as amended. Most of these factors are
outside of Carmell’s control and are difficult to predict.
Furthermore, if the forward-looking statements prove to be
inaccurate, the inaccuracy may be material. In light of the
significant uncertainties in these forward-looking statements, you
should not regard these statements as a representation or warranty
by us or any other person that we will achieve our objectives and
plans in any specified time frame or at all. The forward-looking
statements in this press release represent our views as of the date
of this press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we have no current intention of doing so except to the
extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing our views as of
any date subsequent to the date of this press release.
Contact
Bryan Cassaday
Chief Financial Officer
bc@carmellcorp.com
Carmell (NASDAQ:CTCX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Carmell (NASDAQ:CTCX)
Historical Stock Chart
From Dec 2023 to Dec 2024